Trial Outcomes & Findings for Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea (NCT NCT04446039)

Last Updated: 2024-12-09

Results Overview

Percentage of prescriptions for commonly used antidepressants in acute treatment phase were assessed. Acute treatment phase was during the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period.

Recruitment status

COMPLETED

Target enrollment

370212 participants

Primary outcome timeframe

From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively)

Results posted on

2024-12-09

Participant Flow

Participants who initiated antidepressants between 01-Jan-2018 to 30-Jun-2019 in Health Insurance Review and Assessment (HIRA) service database were observed in this retrospective study. Index date was first prescription date of study drugs during intake period (01-Jan-2018 to 31-Dec-2019). Acute phase was initial 90 days of treatment period and maintenance phase was from 91 to 180 days of treatment. Participants were followed up until 31-Dec-2020.

A total of 370212 participants were included in the study.

Participant milestones

Participant milestones
Measure	Participants With Antidepressant Therapy Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Overall Study STARTED	370212
Overall Study COMPLETED	370212
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Age, Continuous	41.51 Years STANDARD_DEVIATION 15.10 • n=370212 Participants
Sex: Female, Male Female	223994 Participants n=370212 Participants
Sex: Female, Male Male	146218 Participants n=370212 Participants

PRIMARY outcome

Timeframe: From index date (anytime between 01-Jan-2018 to 31-Dec-2019) up to 180 days of treatment (data collected and observed retrospectively)

Population: FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

MPR= Days of medication possession from the prescriptions filled in the 180 days divided by (180 days plus + extra days of drug supply from the last prescription fill during the 180 days). MPR by each index drug including escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion is reported in this outcome measure. Index date was first prescription date of study drugs during intake period.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Medication Possession Ratio (MPR) During First 180 Days of Treatment Escitalopram	0.47 Ratio Standard Deviation 0.35
Medication Possession Ratio (MPR) During First 180 Days of Treatment Paroxetine	0.49 Ratio Standard Deviation 0.36
Medication Possession Ratio (MPR) During First 180 Days of Treatment Fluoxetine	0.46 Ratio Standard Deviation 0.34
Medication Possession Ratio (MPR) During First 180 Days of Treatment Sertraline	0.48 Ratio Standard Deviation 0.36
Medication Possession Ratio (MPR) During First 180 Days of Treatment Duloxetine	0.47 Ratio Standard Deviation 0.36
Medication Possession Ratio (MPR) During First 180 Days of Treatment Venlafaxine	0.50 Ratio Standard Deviation 0.36
Medication Possession Ratio (MPR) During First 180 Days of Treatment Desvenlafaxine	0.53 Ratio Standard Deviation 0.36
Medication Possession Ratio (MPR) During First 180 Days of Treatment Mirtazapine	0.47 Ratio Standard Deviation 0.36
Medication Possession Ratio (MPR) During First 180 Days of Treatment Tianeptine	0.39 Ratio Standard Deviation 0.33
Medication Possession Ratio (MPR) During First 180 Days of Treatment Vortioxetine	0.50 Ratio Standard Deviation 0.35
Medication Possession Ratio (MPR) During First 180 Days of Treatment Bupropion	0.45 Ratio Standard Deviation 0.34

PRIMARY outcome

Timeframe: From index date (anytime between 01-Jan-2018 to 31-Dec-2019) up to 180 days of treatment (data collected and observed retrospectively)

Persistence was defined as the average length of treatment on the index drugs (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion), allowing 14-day permissible gap. Index date was first prescription date of study drugs during intake period.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Persistence During First 180 Days of Treatment Escitalopram	76.11 Days Standard Deviation 67.04
Persistence During First 180 Days of Treatment Paroxetine	79.83 Days Standard Deviation 68.43
Persistence During First 180 Days of Treatment Fluoxetine	74.17 Days Standard Deviation 65.32
Persistence During First 180 Days of Treatment Sertraline	77.34 Days Standard Deviation 67.64
Persistence During First 180 Days of Treatment Duloxetine	71.66 Days Standard Deviation 67.64
Persistence During First 180 Days of Treatment Venlafaxine	79.80 Days Standard Deviation 68.79
Persistence During First 180 Days of Treatment Desvenlafaxine	87.13 Days Standard Deviation 68.81
Persistence During First 180 Days of Treatment Mirtazapine	73.12 Days Standard Deviation 66.78
Persistence During First 180 Days of Treatment Tianeptine	54.48 Days Standard Deviation 60.14
Persistence During First 180 Days of Treatment Vortioxetine	81.44 Days Standard Deviation 66.50
Persistence During First 180 Days of Treatment Bupropion	71.96 Days Standard Deviation 63.82

PRIMARY outcome

Timeframe: From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively)

Percentage of participants who discontinued the treatment in first 90 days from the index date is reported in this outcome measure. Index date was the first prescription date of study treatment during the intake period.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Escitalopram	14.82 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Paroxetine	15.16 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Fluoxetine	15.14 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Sertraline	14.87 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Duloxetine	17.04 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Venlafaxine	14.04 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Desvenlafaxine	12.81 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Mirtazapine	15.21 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Tianeptine	22.27 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Vortioxetine	12.94 Percentage of participants
Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date Bupropion	14.34 Percentage of participants

PRIMARY outcome

Timeframe: From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 180 days of treatment (data collected and observed retrospectively)

Adherence was defined when MPR \>= 75%. MPR = (Days of medication possession from the prescriptions filled in the 180 days) / (180 days + extra days of drug supply from the last prescription fill during the 180 days. Index date was the first prescription date of study drugs during the intake period.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Desvenlafaxine	37.20 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Escitalopram	30.31 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Paroxetine	33.18 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Fluoxetine	27.92 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Sertraline	31.48 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Duloxetine	30.73 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Venlafaxine	33.39 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Mirtazapine	30.32 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Tianeptine	20.75 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Vortioxetine	32.51 Percentage of participants
Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) Bupropion	27.16 Percentage of participants

PRIMARY outcome

Timeframe: From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively)

Recurrence during the acute treatment phase was defined as either one of the following: 1) Inpatient episode with a diagnosis code. 2) Inpatient episodes via the department of psychiatry or emergency medicine. 3) Inpatient episode via nursing hospital. 4) Emergency room visit with a diagnosis code. 5) Suicide attempt. Acute phase considered as the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period. Diagnosis codes used for inclusion were: F06.3-Organic mood(affective) disorders, F32\*- Depressive episode, F33\*- Recurrent depressive disorder, F34.1- Neurotic depression, F38.1- Other recurrent mood(affective) disorders, F41.2- Mixed anxiety and depressive disorder.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Escitalopram	16.42 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Paroxetine	17.84 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Fluoxetine	15.64 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Sertraline	16.73 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Duloxetine	17.97 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Venlafaxine	17.73 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Desvenlafaxine	20.85 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Mirtazapine	19.51 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Tianeptine	16.34 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Vortioxetine	17.62 Percentage of participants
Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase Bupropion	16.13 Percentage of participants

PRIMARY outcome

Timeframe: From day 91 to day 180 from the index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively)

Recurrence was defined as either one of the following: 1) Inpatient episode with a diagnosis code. 2) Inpatient episodes via the department of psychiatry or emergency medicine. 3) Inpatient episode via nursing hospital. 4) Emergency room visit with a diagnosis code. 5) Suicide attempt; antidepressant prescription after 30 days of drug holiday. Acute phase considered as the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Escitalopram	22.71 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Paroxetine	23.58 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Fluoxetine	23.74 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Sertraline	22.91 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Duloxetine	25.48 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Venlafaxine	23.36 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Desvenlafaxine	23.81 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Mirtazapine	24.64 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Tianeptine	27.80 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Vortioxetine	22 Percentage of participants
Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase Bupropion	21.85 Percentage of participants

PRIMARY outcome

Timeframe: From 91 up to 180 days of treatment from index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively)

An AE was any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. Maintenance phase was during the second 90-day period (91 to 180 days) starting from the index date. Index date was the first prescription date of study treatment during the intake period. Index date was the first prescription date of study treatment during the intake period.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Sertraline	6.09 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Escitalopram	6.08 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Paroxetine	6.44 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Fluoxetine	4.29 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Duloxetine	9.59 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Venlafaxine	6.48 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Desvenlafaxine	7.50 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Mirtazapine	10.36 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Tianeptine	8.66 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Vortioxetine	5.34 Percentage of Participants
Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment Bupropion	4.68 Percentage of Participants

PRIMARY outcome

Timeframe: From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively)

Population: FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=2574691 Prescriptions for antidepressants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Escitalopram	44.19 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Paroxetine	10.1 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Fluoxetine	12.15 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Sertraline	8.89 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Duloxetine	2.3 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Venlafaxine	3.21 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Desvenlafaxine	1.75 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Mirtazapine	4.1 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Tianeptine	5.52 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Vortioxetine	4.81 Percentage of prescriptions
Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase Bupropion	2.88 Percentage of prescriptions

PRIMARY outcome

Timeframe: At index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively)

Population: FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018, to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows.

Index date was the first prescription date of study treatment during the intake period.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=370212 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Average Daily Dosage at Index Date Escitalopram	6.34 Milligrams per day Standard Deviation 3.23
Average Daily Dosage at Index Date Paroxetine	13.01 Milligrams per day Standard Deviation 5.50
Average Daily Dosage at Index Date Fluoxetine	16.30 Milligrams per day Standard Deviation 8.55
Average Daily Dosage at Index Date Sertraline	38.75 Milligrams per day Standard Deviation 19.56
Average Daily Dosage at Index Date Duloxetine	34.80 Milligrams per day Standard Deviation 12.91
Average Daily Dosage at Index Date Venlafaxine	54.11 Milligrams per day Standard Deviation 29.12
Average Daily Dosage at Index Date Desvenlafaxine	51.91 Milligrams per day Standard Deviation 11.32
Average Daily Dosage at Index Date Mirtazapine	8.71 Milligrams per day Standard Deviation 5.56
Average Daily Dosage at Index Date Tianeptine	24.28 Milligrams per day Standard Deviation 9.24
Average Daily Dosage at Index Date Vortioxetine	6.03 Milligrams per day Standard Deviation 2.62
Average Daily Dosage at Index Date Bupropion	152.97 Milligrams per day Standard Deviation 53.43

PRIMARY outcome

Timeframe: From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively)

Population: FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Overall Number of Participants Analyzed' signifies number of participants who were treated with monotherapy and 'Number Analyzed' signifies participants evaluable for the specified rows.

Acute treatment phase was during the first 90-day period starting from the index date.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=278422 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Average Daily Dosage During the Acute Treatment Phase Bupropion	162.75 Milligrams per day Standard Deviation 67.75
Average Daily Dosage During the Acute Treatment Phase Escitalopram	7.94 Milligrams per day Standard Deviation 4.13
Average Daily Dosage During the Acute Treatment Phase Paroxetine	15.27 Milligrams per day Standard Deviation 7.48
Average Daily Dosage During the Acute Treatment Phase Fluoxetine	19.07 Milligrams per day Standard Deviation 10.34
Average Daily Dosage During the Acute Treatment Phase Sertraline	49.91 Milligrams per day Standard Deviation 30.24
Average Daily Dosage During the Acute Treatment Phase Duloxetine	37.51 Milligrams per day Standard Deviation 16.62
Average Daily Dosage During the Acute Treatment Phase Venlafaxine	69.12 Milligrams per day Standard Deviation 39.98
Average Daily Dosage During the Acute Treatment Phase Desvenlafaxine	63.22 Milligrams per day Standard Deviation 26.91
Average Daily Dosage During the Acute Treatment Phase Mirtazapine	10.46 Milligrams per day Standard Deviation 7.15
Average Daily Dosage During the Acute Treatment Phase Tianeptine	21.71 Milligrams per day Standard Deviation 9.85
Average Daily Dosage During the Acute Treatment Phase Vortioxetine	8.26 Milligrams per day Standard Deviation 3.95

OTHER_PRE_SPECIFIED outcome

Timeframe: From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively)

Population: FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. One participant was evaluable for more than one row.

Percentage of participants who received monotherapy, combination therapy and augmentation therapy during 90 days of treatment were assessed in this outcome measure. Acute treatment phase was during initial 90 days from the index date.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=278422 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Sertraline	74.36 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Sertraline	9.37 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Venlafaxine	67.58 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Venlafaxine	13.11 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Escitalopram	78.92 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Escitalopram	8.91 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: escitalopram	14.01 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Paroxetine	73.10 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Paroxetine	10.91 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: paroxetine	15.18 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Fluoxetine	74.65 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Fluoxetine	10.08 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: fluoxetine	13.52 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: sertraline	14.16 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Duloxetine	68.91 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Duloxetine	12.53 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: duloxetine	14.31 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: venlafaxine	14.69 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Desvenlafaxine	68.56 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Desvenlafaxine	13.48 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: desvenlafaxine	17.86 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Mirtazapine	71.22 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Mirtazapine	13.01 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: mirtazapine	15.92 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Tianeptine	65.33 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Tianeptine	14.13 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: tianeptine	13.04 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Vortioxetine	72.53 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Vortioxetine	10.45 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: vortioxetine	15.56 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Monotherapy: Bupropion	66.85 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Combination: Bupropion	17.12 Percentage of Participants
Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase Augmentation therapy: bupropion	13.78 Percentage of Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: From 90 days to 180 days of treatment (data collected and observed retrospectively)

The drug utilization pattern is presented according to the average treatment duration for each antidepressant during the maintenance treatment phases.

Outcome measures

Outcome measures
Measure	Participants With Antidepressant Therapy n=185842 Participants Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed.
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Fluoxetine	56.07 Days Standard Deviation 27.30
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Sertraline	59.58 Days Standard Deviation 26.95
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Duloxetine	59.25 Days Standard Deviation 27.64
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Venlafaxine	61.17 Days Standard Deviation 26.61
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Desvenlafaxine	63.65 Days Standard Deviation 26.05
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Mirtazapine	60.92 Days Standard Deviation 27.17
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Tianeptine	51.93 Days Standard Deviation 29.53
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Vortioxetine	60.91 Days Standard Deviation 26.40
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Bupropion	57.34 Days Standard Deviation 27.18
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Escitalopram	59.05 Days Standard Deviation 27.21
Drug Utilization Pattern of Participants During 90-180 Days of Treatment Paroxetine	60.50 Days Standard Deviation 26.73

Adverse Events

Participants With Antidepressant Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER